The GLP‑1 Inflection Point: Why Transparency is Reshaping Pharmacy Strategy

Turning today’s GLP‑1 pressure into tomorrow’s sustainable pharmacy management model

A Shift Bigger Than GLP‑1s

GLP‑1 therapies have rapidly evolved from a clinical breakthrough into one of the most material cost and strategy challenges facing health plans. What began as a diabetes treatment and later expanded into obesity has become a defining example of how high-cost drug economics are shifting across the system. While these therapies are not always classified as specialty drugs and unit costs are declining, the potential for widespread, long-term utilization is creating meaningful financial exposure across pharmacy benefits.

But GLP‑1 market impact is not the story in isolation.

The more profound shift is being driven by CAA‑enabled transparency regulations, which is exposing the true economics of pharmacy benefits. This includes rebates, administrative fees, pharmacy benefit manager (PBM) compensation models, and net cost variability. GLP‑1s are simply the category where these dynamics have become impossible to ignore.

Despite this, a common refrain persists: Meaningful regulatory and transparency requirements tied to the Consolidated Appropriations Act (CAA) will be fully realized until later in the decade. As a result, some organizations are deferring action, but that approach is increasingly risky. By waiting, they risk being unprepared for the structural changes that will accelerate as transparency expands and exposes underlying weaknesses in pharmacy benefit management.

For health plans, this moment represents a structural inflection point. It is one that demands a reassessment of how pharmacy strategy is evaluated, contracted, and governed. The window for proactive adaptation is narrowing, and those who delay may face far more disruptive challenges as transparency requirements take hold.

Riding the Unfolding Cost Curve: Responding to Today’s Financial Reality

GLP-1 cost exposure is not the result of a single trend, but rather the convergence of several key drivers that create a powerful multiplier effect. For health plans, this means the financial impact is far from linear and can escalate quickly, even with modest increases in utilization. The principal factors fueling this effect include:

High unit cost per prescription

Rapidly expanding eligible patient populations

Chronic, long-term therapy durations

Broadening clinical indications beyond diabetes and obesity

The combined effect of these factors is that even modest increases in GLP-1 adoption can drive outsized financial impact. As utilization scales, health plans can experience meaningful per-member-per-month (PMPM) cost increases, putting immediate pressure on medical loss ratios (MLR) and challenging the adequacy of current premiums. While implications vary by line of business, Medicaid strategies are more tightly shaped by state-level coverage decisions, rebate structures, and policy constraints.

At the same time, health plans must weigh rising pharmacy costs against the potential for improved clinical and quality outcomes. Increased GLP-1 utilization can positively influence quality performance metrics, including HEDIS and Stars measures for diabetes and cardiovascular health. The core challenge is balancing these quality gains with disciplined cost management across benefit design and contracting strategies.

Importantly, this cost curve is already emerging across commercial, Medicare Advantage, and Medicaid populations. As GLP‑1 spend becomes concentrated in a relatively small number of high‑cost therapies, even small misalignments in strategy or contract terms are magnified. Commercial and Medicare Advantage plans face greater exposure to utilization growth and benefit flexibility, reinforcing the need for proactive, line‑specific management by health plan leaders.

A Broader Specialty Signal

The landscape of specialty pharmacy drug management has historically exerted substantial pressure on high-cost drug spend due to expensive and often long-term treatments. Now, GLP-1s are introducing similar financial dynamics, but across a much broader patient population, rapidly exposing structural vulnerabilities in how health plans manage and finance high-cost therapies.

What’s unique is that market dynamics are outpacing regulatory timelines: Consumer and employer demand for GLP‑1 therapies is rising sharply, pharmaceutical manufacturers are pursuing direct-to-consumer and alternative access models, oral GLP‑1 options are lowering barriers for patient initiation, and clinical guidelines are evolving toward earlier use. These forces are accelerating utilization today; well ahead of policy changes expected as early as August 2028. What GLP‑1 treatment is surfacing today extends beyond weight loss or metabolic health.

Emerging indications, including cardiometabolic disease expansion and early research into behavioral health applications, suggest that the economic dynamics currently visible in GLP-1 utilization will likely repeat across other therapeutic categories. Emerging cell and gene therapies, as well as treatments for cardiovascular disease are expected to challenge traditional actuarial models. Although the disruption profile may differ across these areas, the need for a coordinated strategic approach is consistent.

From Visibility to Strategic Alignment

Increasing transparency, driven in part by the CAA, is fundamentally reshaping PBM and contracting strategies for health plans. As payers grapple with the surge in GLP-1 utilization and the associated financial pressures, traditional rebate optimization tactics are no longer sufficient.

Health plans now need a more coordinated strategy that aligns contracting, financial planning, and clinical management to respond effectively to this changing pharmacy landscape.

Regulatory and Contract Alignment

As transparency exposes the limitations of legacy PBM economics, payers must reassess contract terms and anticipate evolving regulatory expectations. This includes exploring models that drive toward the most clinically appropriate and lowest net cost, while positioning contracts ahead of emerging transparency and compliance requirements. Proactive engagement is essential to ensure both regulatory readiness and financial alignment.

Financial Visibility and Modeling

Enhanced transparency compels payers to develop forward-looking exposure models that account for utilization trends, therapy duration, and line-of-business variation. As GLP-1 therapies increasingly impact PMPM costs, robust financial modeling is essential to anticipate and manage cost exposure, while ensuring contractual structures reflect the realities of high-cost drug concentration.

Clinical and Population Health Alignment

As indications expand and clinical guidelines evolve, health plans must align clinical management with broader population health strategies. Sustainable access and improved outcomes require coordination across contracting, finance, and clinical leadership, ensuring that therapy pathways, duration, and utilization management support both clinical and financial objectives.

This is not only a pharmacy issue. Health plans must adopt integrated strategies to support coordinated action across contracting, finance, and clinical leadership. Health plans that align these three areas will be better positioned to manage cost exposure, support sustainable access, and improve clinical outcomes as pharmacy benefit economics continue to evolve.

From Insight to Action: How Leading Plans Are Moving Forward

Leading health plans are embracing a strategic shift from traditional utilization control to enterprise-wide alignment. Managing GLP-1 exposure now demands coordinated strategies that connect financial decision-making with clinical outcomes and quality performance metrics. By moving beyond siloed solutions and uniting financial, clinical, and operational leadership, organizations can maintain sustainable access, support population health, and stay agile. Those that act decisively today will be best positioned to deliver value and improved outcomes in the face of ongoing change.

Explore how AArete’s Pharmacy Solutions support health plans as they navigate evolving pharmacy economics and GLP‑1 strategy.

To explore AArete’s Total Cost of Care solutions, click here.